News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt https://seekingalpha.com/article/4722488-immunitybio-anktiva-launch-good-data-low-cash-high-debt?mailingid=36816641&messageid=must_reads&serial=36816641.1512119&source=email_must_reads&utm_campaign=Must%2BReads%2Brecurring%2B2024-09-22&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung  Cancer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-presents-positive-long-term-overall-survival-data?field_nir_news_date_value[min]=

https://www.fiercepharma.com/pharma/cash-crunched-immunitybio-heels-fda-nod-lays-staffers-california-colorado

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval https://finance.yahoo.com/news/immunitybio-anktiva-now-covered-more-124600852.html

https://ir.immunitybio.com/financial-information/sec-filings

https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-study-anktivar-combination-adher2dc-cancer

https://investorplace.com/2024/07/3-top-cancer-treatment-stocks-to-buy-now/